Advertisement

International Journal of Clinical Oncology

, Volume 24, Issue 10, pp 1197–1203 | Cite as

Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study

  • Seiichiro Mitani
  • Shigenori KadowakiEmail author
  • Hiroko Hasegawa
  • Takeru Wakatsuki
  • Hiroki Hara
  • Masahiro Tajika
  • Kazuhiro Nishikawa
  • Motohiro Hirao
  • Daisuke Takahari
  • Keisho Chin
  • Kei Muro
Original Article
  • 146 Downloads

Abstract

Background

S-1 monotherapy is one of the standard adjuvant treatments for patients with stage II and III gastric cancers. Early recurrence after S-1 adjuvant therapy has a poor prognosis. This study aimed to clarify the treatment outcomes of systemic chemotherapy and explore encouraging regimens.

Methods

This was a multicenter retrospective study. Among gastric cancer patients who underwent curative gastrectomy followed by adjuvant S-1 monotherapy, patients who experienced a recurrence while receiving adjuvant therapy or within 6 months after completion and started systemic chemotherapy at four institutions between 2005 and 2015 were eligible.

Results

A total of 112 patients were included. The main treatment regimens were weekly paclitaxel (n = 38, 34%), irinotecan plus cisplatin (n = 31, 28%), capecitabine plus cisplatin (n = 7, 6%), and irinotecan monotherapy (n = 6, 5%). For all patients, median progression-free survival and overall survival were 3.7 and 11.4 months, respectively. Among 77 patients with measurable lesions, the overall response and disease control rates were 24.7% and 62.3%, respectively. Multivariate analyses for overall survival showed that Eastern Cooperative Oncology Group performance status 2 [hazard ratio (HR) 3.71; 95% confidence interval (CI) 1.78–7.73] and undifferentiated histological type (HR 2.04; 95% CI 1.35–3.44) were independent prognostic factors, and treatment regimens were not prognostic. Exploratory comparisons did not show statistically significant differences between treatment regimens.

Conclusions

This study of the largest number of patients with early recurrence after S-1 adjuvant monotherapy demonstrated that the prognosis for patients treated by all regimens was similar and poor.

Keywords

Gastric cancer Adjuvant chemotherapy Recurrence 

Notes

Acknowledgements

The authors would like to thank Enago (www.enago.jp) for the English language review.

Funding

This study was conducted with no funding.

Compliance with ethical standards

Conflict of interest

Seiichiro Mitani has received honoraria from Eli Lilly. Shigenori Kadowaki has received honoraria from Eli Lilly, Bayer, Bristol-Myers, Chugai, Ono, and Yakult, and research funding from Eli Lilly, Boehringer Ingelheim, Bristol-Myers, Ono, and Taiho. Hiroki Hara has received honoraria from Chugai, Taiho, Merck Serono, Yakult, Eli Lilly, Ono, Takeda, Bristol-Myers, and research funding from AstraZeneca, Chugai, Merck Serono, MSD, Ono, Taiho, Takeda, Boehringer Ingelheim, Dainippon Sumitomo, Daiichi Sankyo, Eli Lilly, Pfizer, LSK BioPharma, Eisai, and Incyte. Kazuhiro Nishikawa has received honoraria from Chugai, Taiho, Yakult, Eli Lilly, Tsumura, and EA Pharma, and research funding from Yakult and Taiho. Kei Muro has received honoraria from Eli Lilly, Chugai, Merck Serono, Ono, Taiho, Takeda, and Yakult, and research funding from Daiichi Sankyo, Gilead Sciences, Kyowa Hakko Kirin, MSD, Ono, and Shionogi. None of the remaining authors have potential conflicts of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–386CrossRefGoogle Scholar
  2. 2.
    Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820CrossRefGoogle Scholar
  3. 3.
    Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393CrossRefGoogle Scholar
  4. 4.
    Hasegawa H, Fujitani K, Kurokawa Y et al (2010) Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer. Chemotherapy 56:436–443CrossRefGoogle Scholar
  5. 5.
    Aoyama T, Yoshikawa T, Watanabe T et al (2011) Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer 14:150–154CrossRefGoogle Scholar
  6. 6.
    Shitara K, Muro K, Ura T et al (2008) Chemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1. Jpn J Clin Oncol 38:786–789CrossRefGoogle Scholar
  7. 7.
    Shitara K, Morita S, Fujitani K et al (2012) Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. Gastric Cancer 15:245–251CrossRefGoogle Scholar
  8. 8.
    Nishikawa K, Tsuburaya A, Yoshikawa T et al (2018) A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. Gastric Cancer 21:811–818CrossRefGoogle Scholar
  9. 9.
    Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefGoogle Scholar
  10. 10.
    Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221CrossRefGoogle Scholar
  11. 11.
    Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26:141–148CrossRefGoogle Scholar
  12. 12.
    Chau I, Norman AR, Cunningham D et al (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395–2403CrossRefGoogle Scholar
  13. 13.
    Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39CrossRefGoogle Scholar
  14. 14.
    Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235CrossRefGoogle Scholar
  15. 15.
    Bando H, Shimodaira H, Fujitani K et al (2018) A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer 91:86–91CrossRefGoogle Scholar
  16. 16.
    Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461–2471CrossRefGoogle Scholar
  17. 17.
    Muro K, Chung HC, Shankaran V et al (2016) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17:717–726CrossRefGoogle Scholar
  18. 18.
    Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4:e180013CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Seiichiro Mitani
    • 1
  • Shigenori Kadowaki
    • 1
    Email author
  • Hiroko Hasegawa
    • 2
  • Takeru Wakatsuki
    • 3
  • Hiroki Hara
    • 4
  • Masahiro Tajika
    • 5
  • Kazuhiro Nishikawa
    • 6
  • Motohiro Hirao
    • 6
  • Daisuke Takahari
    • 3
  • Keisho Chin
    • 3
  • Kei Muro
    • 1
  1. 1.Department of Clinical OncologyAichi Cancer Center HospitalNagoyaJapan
  2. 2.Department of GastroenterologyOsaka National HospitalOsakaJapan
  3. 3.Department of Gastroenterology, Cancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan
  4. 4.Department of GastroenterologySaitama Cancer CenterSaitamaJapan
  5. 5.Department of EndoscopyAichi Cancer Center HospitalNagoyaJapan
  6. 6.Department of SurgeryOsaka National HospitalOsakaJapan

Personalised recommendations